5/7
04:30 pm
rare
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
Low
Report
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
5/6
02:22 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $111.00 to $109.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $111.00 to $109.00. They now have a "buy" rating on the stock.
5/4
10:29 am
rare
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results [Yahoo! Finance]
Low
Report
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results [Yahoo! Finance]
5/3
02:04 pm
rare
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
Medium
Report
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
5/3
11:21 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
5/3
09:57 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Wedbush from $48.00 to $47.00. They now have a "neutral" rating on the stock.
Medium
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Wedbush from $48.00 to $47.00. They now have a "neutral" rating on the stock.
5/2
09:54 pm
rare
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Medium
Report
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
5/2
06:50 pm
rare
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates [Yahoo! Finance]
5/2
04:13 pm
rare
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]
Low
Report
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]
5/2
04:00 pm
rare
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
Medium
Report
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
4/30
04:14 pm
rare
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease [Yahoo! Finance]
Low
Report
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease [Yahoo! Finance]
4/30
04:00 pm
rare
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
Low
Report
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
4/30
08:17 am
rare
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) [Yahoo! Finance]
Medium
Report
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) [Yahoo! Finance]
4/30
08:00 am
rare
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Medium
Report
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
4/25
04:30 pm
rare
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Low
Report
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
4/24
01:38 pm
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.
4/22
08:09 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
4/19
04:30 pm
rare
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/16
01:19 pm
rare
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study [Yahoo! Finance]
Medium
Report
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study [Yahoo! Finance]
4/16
10:55 am
rare
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
Low
Report
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
4/15
07:10 am
rare
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 [Yahoo! Finance]
Medium
Report
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 [Yahoo! Finance]
4/15
07:00 am
rare
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Medium
Report
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
4/12
04:33 pm
rare
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome [Yahoo! Finance]
Medium
Report
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome [Yahoo! Finance]
4/12
04:22 pm
rare
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Medium
Report
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
4/12
08:14 am
rare
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]
Medium
Report
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting [Yahoo! Finance]